By
Adrianne Appel2024-12-18T18:08:00
Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission (SEC) said.
Manufacturers are required to get approvals from the Food and Drug Administration (FDA) for complex medical devices like infusion pumps.
The FDA approval process involves submitting detailed data showing a device is safe and effective. BD, one of the largest device manufacturers in the world, with 70,000 employees, received 10 percent of its profits from sales of the pump.
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
2026-02-03T22:57:00Z By Adrianne Appel
Three former executives at Archer-Daniels-Midland intentionally misled investors by inflating the performance of the company’s Nutrition unit, the U.S. Securities and Exchange Commission has alleged.
2024-05-30T19:00:00Z By Adrianne Appel
Medical device manufacturer Innovasis and two of its top executives agreed to pay a total of $12 million to settle allegations originally brought by a whistleblower that they paid kickbacks to physicians.
2023-04-05T15:36:00Z By CW Staff
Global medical technology firm Becton, Dickinson and Company announced the promotion of Chief Ethics and Compliance Officer Michelle Quinn to general counsel.
2026-03-19T21:08:00Z By Aaron Nicodemus
The U.S. Securities and Exchange Commission’s Mark Uyeda told an audience of investment advisers that the SEC will no longer prioritize stand-alone enforcement actions for violations of the SEC’s rules on off-channel communications.
2026-03-17T21:22:00Z By Oscar Gonzalez
Adobe agreed to a $150 million settlement with the U.S. Department of Justice over accusations that it concealed software termination fees and made it difficult for customers to cancel.
2026-03-13T21:06:00Z By Neil Hodge
New powers granted to the U.K.’s main competition watchdog will result in greater scrutiny, tougher enforcement, and a stark warning for companies to review their sales and marketing promotions—especially since some practices have been pushed firmly into the spotlight thanks to legislation that came into effect last year.
Site powered by Webvision Cloud